Long-term follow-up of a case of choroidal neovascularization secondary to reticular pigmentary retinal dystrophy / Seguimento de longo-prazo de um caso de neovascularização de coroide secundária à distrofia reticular pigmentar da retina

ABSTRACT Reticular pigmentary retinal dystrophy, also known as Sjögren's reticular dystrophy, is a rare condition characterized by macular lesions with a reticular pattern, which are best seen on fluorescein angiogram. Choroidal neovascularization secondary to this type of dystrophy is even less common. This report describes a case of reticular pigmentary retinal dystrophy with vision loss due to neovascular membrane, which responded well to treatment with anti-vascular endothelial growth factor.

RESUMO A distrofia reticular pigmentar da retina, também conhecida como distrofia reticular de Sjögren, é uma doença rara, caracterizada por lesões maculares com um padrão reticular, que são mais bem visualizadas na angiografia com fluoresceína. A neovascularização de coroide secundária a este tipo de distrofia é ainda menos comum. Este relato descreve um caso de distrofia reticular pigmentar da retina, com perda de visão devido à membrana neovascular, que respondeu bem ao tratamento com fator de crescimento endotelial antivascular.

An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration / 浙江大学学报（英文版）（B辑：生物医学和生物技术）

OBJECTIVE@#To evaluate the effect of anti-vascular endothelial growth factor (VEGF) on juxtafoveal choroidal neovascularization (CNV) secondary to multifocal choroiditis (MFC) and wet age-related macular degeneration (AMD).@*METHODS@#In this retrospective, comparative study, 20 unique eyes with CNV were divided into two groups: 10 patients affected by MFC and 10 patients diagnosed with wet AMD. They all received local intravitreal (IVT) injections of ranibizumab, with 6 months of follow-up. Retreatment injections were performed based on findings suggestive of active neovascularization.@*RESULTS@#Significant improvements were observed in the juxtafoveal CNV lesions, and average central macular thickness decreased in both groups following the anti-VEGF therapy (P<0.05). The average number of injections used in MFC patients was 1.6, while three injections on average were used in wet AMD patients (Z=-2.844, P=0.009). Best-corrected visual acuity was significantly improved in MFC patients after anti-VEGF therapy (P<0.05), and there was no significant difference in wet AMD patients between before anti-VEGF therapy and 6 months later (P>0.05).@*CONCLUSIONS@#IVT ranibizumab resulted in good clinical outcomes for juxtafoveal CNV secondary to MFC and wet AMD, but the average number of injections used in MFC was fewer than that used in wet AMD over a 6-month observation period. Compared with the wet AMD group, visual acuity was obviously improved in the MFC group at 6 months.

Choroidal neovascularization silent on optical coherence tomography: report of two cases / Neovascularização de coroide silente a tomografia de coerência ótica: relato de dois casos

ABSTRACT Herein, we report two cases of vision loss after successful cataract surgery, associated with drusenoid retinal pigment epithelial detachment without features of choroidal neovascularization on optical coherence tomography along with angiographic examinations suggestive of choroidal neovascularization in which anatomical and functional improvements were achieved with intravitreal injections of anti-vascular endothelial growth factor.

RESUMO Relatamos dois casos de baixa visual após cirurgia bem sucedida de catarata, associada a descolamento drusenóide do epitélio pigmentar da retina (DPED) sem achados de neovascularização de coroide a tomografia de coerência óptica OCT (CNV silente ao OCT) e com exames angiográficos sugestivos de neovascularização da coroide (CNV), nos quais melhoras anatômicas e funcionais foram obtidas com aplicações intravítreas de anti-VEGF.

Drastic effect of ranibizumab on choroidal neovascularization in idiopathic angioid streaks / Efeito dramático do ranibizumabe na neovascularização de coroide em estrias angióides idiopáticas

ABSTRACTA 28-year-old man presented with bilateral vision loss. His best-corrected visual acuity (BCVA) was 0.3 in the right eye (OD) and 0.6 in the left eye (OS). Fundoscopy and fluorescein angiography showed angioid streaks encircling the optic discs of both eyes (OU). Spectral Domain Optical Coherence Tomography (SD-OCT) showed bilateral macular serous detachment. Systemic and ocular screening tests showed no specific cause for the angioid streaks. The patient had previously received pegaptanib sodium injection on three occasions, photodynamic therapy in OS, and no treatment in OD. Upon intravitreal injection of ranibizumab (twice in OU), subretinal fluid was nearly eliminated in OU. BCVA increased to 0.6 in OD and 0.9 in OS, and remained improved until 6 months after treatment.

RESUMOUm homem de 28 anos apresentou-se com perda de visão bilateral. A melhor acuidade visual corrigida (BCVA) era 0,3 no olho direito (OD) e 0,6 no olho esquerdo (OS). A fundoscopia e a angiofluoresceinografia demonstraram estrias angióides ao redor dos discos ópticos em ambos os olhos (OU). A tomografia de coerência óptica de domínio espectral (SD-OCT) demonstrou descolamento seroso macular bilateral. Testes de triagem sistêmicas e oculares não mostraram causa específica para estrias angióides. O paciente tinha um historia de três tratamentos com injeção de pegaptanibe sódico e terapia fotodinâmica em OS e nenhum tratamento em OD. Após a injeção intravítrea de ranibizumabe (duas vezes em OU), fluido sub-retiniano quase desapareceu em OU. BCVA melhorou para 0,6 em OD e 0,9 em OS e não se alterou até o sexto mês de tratamento.

Anatomical and visual outcomes of ranibizumab injections in retinal pigment epithelium tears / Resultados anatômicos e visuais de injeções de ranibizumab em roturas do epitélio pigmentado da retina

ABSTRACT Purpose: To report the anatomical and visual results in patients diagnosed as having retinal pigment epithelium (RPE) tears after receiving ranibizumab injections. Methods: Eyes diagnosed as having RPE tears with a minimum 6-month follow-up were retrospectively evaluated. Each eye was treated with at least three doses of ranibizumab at monthly intervals. Best-corrected visual acuity (BCVA), anterior segment findings, intraocular pressure, and fundus examination results were evaluated during control visits. Color fundus photography, fundus fluorescein angiographies, fundus autofluorescence, and spectral domain optical coherence tomography (SD-OCT) images were obtained. The height of pigment epithelial detachment (PED) was measured by SD-OCT. Results: Twelve eyes with RPE tears were studied. Nine eyes (75%) developed RPE tears during ranibizumab injections for choroidal neovascularization (eight eyes with vascularized PED and one eye with choroidal osteoma), and tears occurred in three eyes before any injections. The median number of ranibizumab injections after diagnosis of RPE tears was 3 (min 2, max 5). In the most recent follow-up visit, there was no statistically significant correlation between the grade of RPE and logMAR of BCVA (p>0.05, r=0.112). Eight of twelve eyes had PED, and seven of these had irregular PED contours before injection therapy. The mean PED height was 447 ± 122 µm. Conclusions: In this series, RPE tears developed mostly after intravitreal anti-VEGF injections for vascularized PED. Increased vertical height and irregular contours of the PEDs can be risk factors for the formation of RPE tears. The continuation of anti-VEGF therapy after tear formation is beneficial for vision improvement in eyes with RPE tears. .

RESUMO Objetivo: Apresentar os resultados anatômicos e visuais de injeções de ranibizumab em pacientes que foram diagnosticados com roturas do epitélio pigmentado da retina (RPE). Métodos: Olhos com um mínimo de seis meses de acompanhamento após diagnóstico de roturas do RPE foram avaliados retrospectivamente. Cada olho foi tratado com, pelo menos, três doses de ranibizumab em intervalos mensais. Acuidade visual com a melhor correção (BCVA), achados do segmento anterior, pressão intraocular e exames de fundo de olho foram avaliados nas visitas de controle. Retinografia colorida, angiografias fluoresceínicas, autofluorescência de polo posterior e tomografia de coerência óptica imagens de domínio espectral (SD-OCT) foram obtidos. A altura do descolamento do epitélio pigmentado (PED) foi medida com SD-OCT. Resultados: Doze olhos com roturas do epitélio pigmentado da retina foram incluídos no estudo. Nove olhos (75%) desenvolveram roturas do epitélio pigmentado da retina durante as injeções ranibizumab para neovascularização de coroide (oito olhos com descolamento do epitélio pigmentado vascularizado e um olho com osteoma de coroide), a rotura ocorreu em três olhos antes de quaisquer injeções. A mediana do número de injeções de ranibizumab após o diagnóstico da rotura do RPE foi de 3 (mínimo 2, máximo 5). Na visita de acompanhamento mais recente, não houve correlação estatisticamente significante entre o grau de RPE e logMAR de BCVA (p>0,05, r=0,112). Oito dos doze olhos tinham descolamento do epitélio pigmentado, desses, 7 olhos tinham PEDs com contornos irregulares antes da injeção. A altura média do PED foi 447 ± 122 µm. Conclusões: Nesta série, as roturas de epitélio pigmentado da retina aconteceram principalmente após a injeção intravítrea anti-VEGF para descolamento do epitélio pigmentado vascularizado. O aumento da altura vertical e contornos irregulares dos PEDs podem ser considerados fatores de risco para a formação da rotura ...

Predictive Findings of Visual Outcome in Spectral Domain Optical Coherence Tomography after Ranibizumab Treatment in Age-related Macular Degeneration

PURPOSE: To investigate which spectral domain optical coherence tomography (SD-OCT) findings predict visual outcome after anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular degeneration (NV-AMD). METHODS: We reviewed the medical records of patients with treatment-naive NV-AMD who underwent three or more consecutive anti-VEGF injections. The patients were divided into three groups according to their changes of visual acuity (VA); improved (group I), static (group S), or worsened (group W). We assessed the incidences and values of all available SD-OCT findings of these groups, compared these findings between the three groups and compared the initial values with the post-treatment values. RESULTS: Better initial VA and longer external limiting membrane (ELM) length were associated with less change in VA after anti-VEGF treatment. The initial VA was mildly correlated with initial photoreceptor inner and outer segment junction (IS/OS) length and initial ELM length. The final VA was also mildly correlated with the final IS/OS length and the final ELM length. VA was significantly changed after anti-VEGF treatment in groups W and I. With regard to incidence, disruption of the IS/OS (IS/OS-D), disruption of the ELM (ELM-D) and ELM length differed significantly between the three groups, particularly ELM-D. The incidences of IS/OS-D and ELM-D in group I were significantly lower than those in groups S and W, and those in group S were also lower than those in group W. The ELM length in group I was significantly longer than it was in groups S and W, and the ELM length in group S was longer than that for group W. However, these three findings did not change after the anti-VEGF treatment. CONCLUSIONS: Initial IS/OS-D, ELM length and particularly ELM-D can be useful predictors of the visual outcome after anti-VEGF treatment in NV-AMD patients.

Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity

PURPOSE: To investigate 12-month treatment outcomes of anti-vascular endothelial growth factor therapy in eyes with typical exudative age-related macular degeneration with good baseline visual acuity. METHODS: This retrospective observational case series included 18 eyes (18 patients) with typical exudative age-related macular degeneration with a baseline best-corrected visual acuity of 20 / 25 or better. Patients were treated with anti-vascular endothelial growth factor monotherapy during the 12-month follow-up period. Baseline visual acuity and central foveal thickness were compared to the values at 12 months. RESULTS: Patients received an average of 4.4 +/- 1.3 intravitreal anti-vascular endothelial growth factor injections. The mean logarithm of minimum angle of resolution visual acuity was 0.08 +/- 0.04, 0.08 +/- 0.07, 0.12 +/- 0.09, and 0.16 +/- 0.11 at baseline, three months, six months, and 12 months, respectively. Visual acuity at 12 months was significantly worse than the baseline value at diagnosis (p = 0.017), and the mean central foveal thickness at the defined time points was 270.2 +/- 55.6, 204.4 +/- 25.4, 230.1 +/- 56.3, and 216.8 +/- 48.7 microm, respectively. The central foveal thickness at 12 months was significantly less than the baseline value at diagnosis (p = 0.042). CONCLUSIONS: Deterioration in visual acuity was noted in eyes with typical exudative age-related macular degeneration with good baseline visual acuity, suggesting the need for close patient monitoring and prompt treatment even in patients with good baseline visual acuity.

Bilateral choroidal neovascularization response to unilateral intravitreal Ranibizumab injection in a patient with angioid streaks / Resposta de neovascularização bilateral de coróide à injeção unilateral de Ranibizumabe intravítreo de paciente com estrias angióides

Report of a 48 year-old male with bilateral decrease in vision due to choroidal neovascularization secondary to angioid streaks. Best corrected visual acuity was 20/80 in the right eye and counting fingers at 2 meters on the left eye. Patient underwent intravitreal injection of Ranibizumab (Lucentis) in the eye with worse visual acuity. Fifteen days after treatment patient reported better visual acuity on the fellow eye, which was measured to be 20/25. Treatment result was evaluated with visual acuity and optical coherence tomography. The effect of ranibizumab was observed in the treated eye, but the fellow eye had complete resolution of the choroidal neovascularization complex. This result may be a response to systemic absorption of the medication.

Os autores descrevem paciente do sexo masculino, 48 anos, com diminuição visual bilateral há 15 dias por membrana neovascular sub-retiniana secundária a estrias angióides. A acuidade visual com melhor correção no olho direito era 20/80 e no olho esquerdo de conta dedos a 2 metros. Submetido à injeção intravítrea de Ranibizumabe (Lucentis) no olho com pior acuidade visual. Após 15 dias do tratamento, referiu melhora acentuada da visão no olho contralateral com visão de 20/25. O resultado foi avaliado por meio da acuidade visual e da tomografia de coerência óptica. O efeito do ranibizumabe foi observado no olho tratado, mas no olho contralateral houve completa resolução do complexo da membrana neovascular sub-retiniana. Levanta-se a hipótese de que esse resultado possa ser atribuído à absorção sistêmica da medicação.

Predominantly hemorrhagic choroidal neovascular lesion from exsudative age-related macular degeneration treated with intravitreal ranibizumab therapy / Lesão neovascular predominantemente hemorrágica da degeneração macular relacionada à idade, tratada com ranibizumab intravítrea

The authors relate a predominantly hemorrhagic choroidal neovascular lesion from neovascular. Age-related macular degeneration patient case treated with intravitreal ranibizumab therapy. Monthly ranibizumab (six intravitreal injections) displayed a promising response but this limited report is insufficient to guarantee the indication for all predominantly hemorrhagic choroidal neovascular lesion from neovascular age-related macular degeneration. Further studies will be necessary for complete validation of our results for all predominantly hemorrhagic choroidal neovascular lesions from CNV due to AMD...

Os autores apresentam um caso de paciente com lesão neovascular predominantemente hemorrágica com degeneração macular relacionada à idade, tratada mensalmente com injenções intravítrea com ranibizumab. Discutem sua evolução, que apesar da boa resposta terapêutica, necessita de maiores estudos para confirmação de seus resultados...

Intravitreal bevacizumab combined with infliximab in the treatment of choroidal neovascularization secondary to age-related macular degeneration: case report series / Administração intravítrea de bevacizumabe combinado com infliximabe no tratamento da neovascularização coroidiana secundária à degeneração macular relacionada à idade: relato de uma série de casos

PURPOSE: To evaluate the feasibility of the combined use of bevacizumab (Avastin®) and combined with infliximab (Remicade®) in the treatment of naive choroidal neovascularization due to age-related macular degeneration eyes. METHODS: Intravitreal injections of bevacizumab combined with infliximab in 6 neovascular age-related macular degeneration eyes. All patients underwent complete ophthalmologic examination on the initial visit and at days 1, 30, 60, 90, 120, 150 and 180 following the first injection. Optical coherence tomography and fluorescein angiography were performed during at initial visit and monthly during the 6 months follow-up period. Electroretinography was performed before and 30 days after initial injection, in order to evaluate retinal toxicity induced by such treatment. RESULTS: Thirty days after the first injection, 5 eyes (83%) shown decrease in macular thickness. No change was seen in electroretinogram in any eyes compared to initially performed electroretinogram. All phakic eyes developed cataract. One patient developed vitritis and was submitted to medical treatment successfully. At the end of the 6 months follow-up period, 4 patients showed significant improvement in the exudative process of choroidal neovascularization. One eye had mild persistent submacular fluid without active choroidal neovascularization, and another eye had persistent amount of intraretinal fluid due to active choroidal neovascularization. CONCLUSION: The combined use of bevacizumab with infliximab in eyes with neovascular age-related macular degeneration was effective in reducing leakage and improving the macular thickness. However, it is not possible to assert that the results were related to synergic effects of the combination therapy. A controlled study with more cases is necessary to precisely define the complication rates; however the dosage and/or association of drugs studied in this research should not be recommended in clinical practice due to cataract as well as inflammatory reaction.

OBJETIVO: Avaliar a viabilidade do uso combinado do bevacizumabe (Avastin®) e do infliximabe (Remicade®) no tratamento da degeneração macular relacionada à idade neovascular em pacientes sem tratamentos prévio. MÉTODOS: Foram realizadas injeções intravítreas de bevacizumabe combinado com infliximabe em 6 pacientes portadores de degeneração macular relacionada à idade neovascular. Todos foram submetidos ao exame oftalmológico completo, no primeiro dia de consulta, no dia seguinte a cada injeção e mensalmente até completar seis meses após a primeira injeção. Foram realizados tomografia de coerência óptica e angiografia fluoresceínica na primeira consulta e mensalmente, até completar 6 meses após o primeiro procedimento. Eletrorretinografia também foi realizada antes da injeção e 30 dias após, no intuito de avaliar toxidade retiniana. RESULTADOS: Ao final de 30 dias da primeira injeção, 5 (83%) pacientes apresentaram diminuição na espessura macular. Não foi visualizada alteração à eletrorretinografia em relação ao exame inicial em 100% os pacientes. Cinco pacientes (100% dos fácicos) desenvolveram catarata. Um paciente desenvolveu vitreíte e foi tratado com sucesso. Ao final dos 6 meses, 4 pacientes apresentaram melhora significativa da neovascularização de coroide, porém ainda com foco de neovascularização em atividade, um paciente apresentava discreta persistência de fluido submacular sem neovascularização ativa e 1 paciente persistia importante quantidade de fluido intrarretiniano com neovascularização em atividade. DISCUSSÃO: Avaliou-se o uso combinado do bevacizumabe com infliximabe em pacientes portadores de degeneração macular relacionada à idade neovascular e a associação mostrou-se eficaz na redução do vazamento da neovascularização de coroide e da espessura macular ao tomografia de coerência óptica. Não é possível, no entanto, afirmar se os resultados apresentam efeitos sinérgicos pela associação entre as duas drogas. Um estudo com maior número de casos é necessário para definir exatamente as taxas de catarata e vitreíte da associação entre as drogas, no entanto, ao menos na dosagem estudada no presente trabalho, a associação não deveria ser recomendada na prática clínica.

Potential protective effect of angiopoietin-1 on the leakage of rat choroidal neovascularization

To observe the potential protective effect of angiopoietin-1 [Ang-1] on rat choroidal neovascularization [CNV] leakage. The study was conducted at the Eye Institute of Shandong University of Traditional Chinese Medicine, Jinan, China from June 2012 to June 2013. Thirty CNV model rats were induced by laser. In vivo, fluorescein fundus angiography and pathological techniques were applied to detect the effect of vascular endothelial growth factor [VEGF] and Ang-1 intravitreous injection. In vitro, 3-[4, 5-dimethylthiazole-2-yl]-2, 5-biphenyl tetrazolium bromide [MTT] assay was applied to detect the proliferation of cultured bovine retinal endothelial cells [BRECs] after treatment with VEGF and Ang-1. Transmission electron microscopy [TEM] was used to detect the morphological changes under VEGF and Ang-1. In the CNV rat model, less late leakage was found in the Ang-1 group than the vehicle control or the VEGF group. The MTT assay showed Ang-1 administration inhibited the proliferation of BRECs. The VEGF promoted proliferation at low concentrations and inhibited the proliferation when its concentration reached 50 ng/ml. The administration of VEGF+Ang-1 rescued the inhibition effect of Ang-1 alone. The TEM results showed that there were less intercellular junctions in the VEGF group compared with the vehicle control. In the VEGF + Ang-1 group, the intercellular junctions were nearly normal. The Ang-1 can induce intercellular junction formation and decrease the CNV leakage

Intravitreal ranibizumab and bevacizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic atrophy / Avaliação da resposta da injeção intravítrea de ranibizumab e bevacizumab em pacientes com neovascularização de coroide da degeneração macular relacionada à idade com atrofia geográfica extensa pré-existente

PURPOSE: To report the response of choroidal neovascularization to intravitreal ranibizumab or bevacizumab treatment in the setting of age-related macular degeneration with extensive pre-existing geographic atrophy of the retinal pigment epithelium. METHODS: This is a retrospective case series of 11 eyes in ten consecutive patients retrieved from a photographic database. The patients were treated with ranibizumab or bevacizumab for neovascular age-related macular degeneration with pre-existing geographic atrophy. Patients were included if they had geographic atrophy at or adjacent to the foveal center of at least 1 disc area in size that was present before the development of choroidal neovascularization. The best corrected visual acuity and optical coherence tomography analysis of the central macular thickness were recorded for each visit. Serial injections of ranibizumab or bevacizumab were administered until there was complete resolution of subretinal fluid on optical coherence tomography. Data over the entire follow-up period were analyzed for overall visual and optical coherence tomography changes. RESULTS: The patients received an average of 7 ± 3 intravitreal injections over the treatment period. Seven of 11 eyes had reduced retinal thickening on optical coherence tomography. On average, the central macular thickness was reduced by 72 ± 115 µm. Six of these 7 eyes had improvement of one or more lines of vision and one had no change. The average acuity change for all patients was -0.04 ± 0.46 logMAR units, which corresponded to a gain of 0.2 ± 4.4 lines of Snellen acuity. The treatment resulted in a good anatomic response with resolution of the subretinal fluid and overall stable visual acuity. CONCLUSIONS: The results of this case series suggest that the use of an intravitreal anti-vascular endothelial growth factor (VEGF) agent (ranibizumab or bevacizumab) for choroidal neovascularization in age-related macular degeneration with pre-existing geographic atrophy is effective. Our results are not as striking as published results from large-scale trials of anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization, presumably due to the limitation in the baseline visual acuity caused by the underlying geographic atrophy. The favorable anatomic response with the resolution of subretinal fluid and stable acuity were consistent with other ranibizumab and bevacizumab studies.

OBJETIVO: Avaliação dos resultados da injeção intravítrea de ranibizumab e bevacizumab em pacientes com neovascularização de coróide da degeneração macular relacionada a idade, com atrofia geográfica extensa, pré-existente. MÉTODOS: Este é um estudo retrospectivo de 10 pacientes, 11 olhos com neovascularização de coroide da degeneração macular relacionada à idade, com atrofia geográfica extensa, pré-existente. Os pacientes incluídos apresentaram atrofia geográfica, envolvendo a fóvea ou adjacência, antes do desenvolvimento da neovascularização de coroide. A melhor correção visual e o exame de tomografia de coerência óptica com análise da espessura macular foram registrados em cada visita. As injeções de ranibizumab e bevacizumab intravítrea foram feitas até a resolução do líquido sub-retiniano pela tomografia de coerência óptica e clinicamente. Todos os pacientes tinham seguimento de 6 meses do diagnóstico a 2 anos, com média de 16 meses. RESULTADOS: Onze olhos de 10 pacientes incluídos receberam uma média de 7 ± 3 injeções intravítreas de ranibizumab e bevacizumab, sendo que 7 apresentaram redução do espessamento macular pelo tomografia de coerência óptica. A mácula teve o espessamento reduzido entre 72 ± 115 µm, 6 olhos tiveram melhora de 1 ou mais linhas de visão, um olho teve acentuada diminuição da visão e um outro não teve alteração. A média do resultado do tratamento em logMAR era -0,04 ± 0,46 correlacionando um ganho de visão na tabela de Snellen entre 0,2 ± 4,4 linhas de visão. CONCLUSÕES: Estes resultados sugerem que o uso do ranibizumab e bevacizumab intravítrea para neovascularização de coroide da degeneração macular relacionada à idade em extensa atrofia geográfica pré-existente é eficaz. Há, entretanto dificuldades na avaliação da acuidade visual destes pacientes em virtude da extensa atrofia geográfica que apresentavam e sobre esta ainda a neovascularização de coroide, se comparados a casos em que a neovascularização de coroide não ocorre em atrofia geográfica pré-existente.

Intravitreal bevacizumab for treatment of choroidal neovascularization associated with osteogenesis imperfecta.

A 12-year-old girl, diagnosed of osteogenesis imperfecta, presented with sudden visual loss in the left eye. Investigations revealed an active choroidal neovascular membrane. She underwent treatment with intravitreal Bevacizumab (1.25 mg/0.05 ml). Follow-up at 1 month revealed the development of lacquer crack running through the macula, underlying the fovea. The patient received two re-treatments at 1-month intervals, following which the choroidal neovascularization (CNV) regressed completely. However, further progression of lacquer cracks was noted. At the last follow-up, 6 months following the last injection, the fundus remained stable and vision was maintained at 20/200. Considering the natural history of the disease and the increased risk of rupture of the Bruch's membrane in such eyes, the possible complication of a lacquer crack developing must be borne in mind, before initiating treatment.

Ranibizumab for choroidal neovascular membrane in a rare case of Bietti's crystalline dystrophy: A case report.

We report a rare case of Bietti's crystalline dystrophy presenting with choroidal neovascular membrane (CNVM) which was treated with three injections of intravitreal ranibizumab. The CNVM underwent scarring after the injections with stabilization of visual acuity at a follow-up period of 12 months suggesting that intravitreal ranibizumab may have a role in the management of CNVM in these rare cases.

Tratamento da DMRI exsudativa: revisão das drogas antiangiogênicas / Wet-amd treatment: a review in the anti-vegf drugs

Degeneração Macular Relacionada à Idade (DMRI) exsudativa é a principal causa de perda visual severa em indivíduos acima de 50 anos nos países desenvolvidos. O fator de crescimento endotelial (VEGF) é considerado um dos mais importantes reguladores da angiogênese e da permeabilidade vascular . Drogas com atividade antiVEGF tem se mostrado eficaz em preservar ou melhorar a acuidade visual (AV) ao inibir a permeabilidade vascular e o crescimento neovascular nos pacientes tratados. Este artigo de revisão descreve o atual uso terapêutico das medicações antiVEGF para DMRI exsudativa e fornece uma visão geral do futuro da terapia antiangiogênica.

Neovascular age-related macular degeneration is the leading cause of severe, irreversible vision loss in individuals over 50 years in developed countries. Vascular endothelial growth factor (VEGF) has been shown to play a role in the regulation of choroidal neovascularization and vascular permeability. Anti-VEGF drugs have been shown to preserve or improve visual acuity by inhibiting vascular permeability and arresting the growth of neovascularization in the vast majority of treated patients. This review describes the current literature on the use of this therapeutic approach in the management of neovascular AMD and gives an overview of the future directions.

Combination therapy of low-fluence photodynamic therapy and intravitreal ranibizumab for choroidal neovascular membrane in choroidal osteoma.

Choroidal osteoma is an unusual form of intraocular calcification seen in otherwise healthy eyes. It is a benign idiopathic osseous tumor of the choroid, typically seen in young females. Choroidal neovascular membrane (CNVM) is a complication seen in one-third of these patients and carries a poor visual outcome. We report a case of a 25-year-old hyperthyroid female with choroidal osteoma and subfoveal CNVM in her left eye which was successfully treated using low-fluence photodynamic therapy (PDT) with verteporfin followed by a single injection of intravitreal ranibizumab.

Tratamento da degeneração macular relacionada à idade com neovascularização de coróide extrafoveal: análise de uma série de casos e revisão de literatura / Treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration: analysis of a cases series and revision paper

A degeneração macular relacionada à idade (DMRI) é uma doença degenerativa da área central da retina freqüentemente associada à perda visual central, em pessoas acima de 55 anos de ambos os sexos, sendo a mais importante causa de cegueira irreversível em adultos nos países desenvolvidos e a terceira causa de cegueira no mundo. OBJETIVO: Avaliar a eficácia da injeção intravítrea de Ranibizumab (anti-VEGF) no tratamento da neovascularização de coróide não subfoveal, podendo ser extrafoveal ou justafoveal, causada pela degeneração macular relacionada à idade exsudativa e revisão da literatura. MÉTODOS: Foi realizado um estudo descritivo e transversal com avaliação de quinze pacientes com neovascularização de coróide extrafoveal ou justafoveal causada por degeneração macular relacionada à idade. Os pacientes foram tratados com uma injeção intravítrea, por mês, no mínimo por três meses consecutivos, de Ranibizumab na dose de 0,5mg, no olho com neovascularização de coróide. Os mesmos foram examinados com um mês de intervalo entre as aplicações das injeções e acompanhados com exames complementares. RESULTADOS: Os resultados da análise dos quinze pacientes que foram incluídos nesta série de casos mostraram que onze (73,3 por cento) pacientes apresentavam neovascularização de coróide extrafoveal e quatro (26,6 por cento) justafoveal. Oito (53,3 por cento) apresentavam a forma oculta e sete (46,6 por cento) tinham lesões clássicas. A média de injeções realizadas foi de 3,67, sendo o menor número de injeções 3 e o maior 6 injeções. Oito (53,3 por cento) pacientes apresentaram resolução do quadro exsudativo neovascular com o máximo de três injeções e apenas um (6,67 por cento) paciente necessitou de seis injeções para resolução do seu quadro. A acuidade visual máxima alcançada foi de 20/30, e ocorreu em cinco (33,3 por cento) pacientes. A média de acuidade visual no momento do diagnóstico foi de 0,44logMAR e a média final de 0,27logMAR Na avaliação final dos pacientes após os seis meses de estudo, a média de linha de visão ganha foi de 1,87 linha de acuidade visual pela tabela de Snellen, sendo que todos os 15 pacientes ganharam uma ou mais linhas de visão. CONCLUSÃO: No tratamento dos pacientes com degeneração macular relacionada à idade e neovascularização de coróide extrafoveal a injeção de Ranibizumab mostrou-se eficaz, podendo ser a opção como indicação inicial de tratamento nestes casos.

Age-related macular degeneration is a major cause of central vision loss and is the leading cause of blindness for people aged over 60 years. PURPOSE: To investigate the efficacy of intravitreal injection of Ranibizumab (anti-VEGF) in the treatment of choroidal neovascularization nonsubfoveal, extra-foveal or juxta-foveal, caused by age-related macular degeneration and revision paper. METHODS: The study design was descriptive and transverse.15 patients with nonsubfoveal choroidal neovascularization caused by age-related macular degeneration, were treated with intravitreal injection of Ranibzumab per month, at least for three consecutive months. Patients were examined at one month interval between the injections and evaluated using visual acuity testing with Snellen charts, fluorescein angiography, and optical coherence tomography scans. RESULTS: There were 11extra-foveal lesions (73.3 percent) and 4 juxta-foveal lesions (26.6 percent). Seven lesions were predominantly classic (46.6 percent) and eight lesions were occult (53,3 percent). The mean number of injections performed was 3.67 and the lowest number of injections 3 and 6 larger injections. Eight (53.3 percent) patients had complete resolution of the exudative neovascular condition with a maximum of three injections and only one (6.67 percent) patient required six injections to resolution his condition. The best visual acuity achieved was 20/30, and occurred in five (33.3 percent) patients. The mean visual acuity at diagnosis was 0.44 logMAR and 0.27 logMAR final average. In the final evaluation of patients after six months of study, the average line of sight gains were 1.87 line of visual acuity by Snellen chart. All 15 patients gained one or more lines of vision. CONCLUSION: In the treatment of patients with nonsubfoveal choroidal neovascularization in age-related macular degeneration, injection of Ranibizumab was effective and could be an option as an indication of initial treatment in these cases.

Polypoidal choroidal vasculopathy causing cystoid macular edema and the response to Ranibizumb intravitreal treatment / Vasculopatia coroidiana polipoidal causando edema macular cistóide e a resposta ao tratamento com Ranibizumab

PURPOSE: To report a polypoidal vascular choroidopathy clinical case causing cystoid macular edema and the response to Ranibizumab intravitreal treatment. METHODS: A 62-year old caucasian woman was referred by her comprehensive ophthalmologist for retinal avaliation. On presentation best corrected visual acuity was 20/100 in the left eye and 20/20 in right eye.Anterior segment examination was unremarkable in both eyes. Clinical examination and FA on the left eye demonstrated numerous small drusen and a cystoid macular edema due leakage from any polips in justapapilar region and from polips in the superior arcade vascular region and subretinal fluid and cystic change in the OCT.The right eye had FA normal. The patient refused to submitt a ICGV angiography. The patient was treated by intravitreal ranibizumab injections in the left eye every 4 weeks, 3 injections ,three months. RESULTS: The patient showed resolution both of cystic change and subretinal fluid in the OCT, and the visual acuity in the six months follow-up improved to 20/25. The patient was followed by 18 months at this time and the visual acuity remained stable 20/25. CONCLUSION: We reported a patient case of cystoid macular edema from a polypoidal choroidal vaculopathy that responded well to ranibizumab intravitreal injection as monotheraphy with disappearance of the initial subretinal fluid and cystic change in OCT follow-up and stop the polips.

OBJETIVO: Relatar um caso de paciente com Vasculopatia coroidiana polipoidal com edema macular cistóide e a resposta ao tratamento com Ranibizumab intravítrea como monoterapia MÉTODOS: Uma paciente com 62 anos foi referida por seu oftalmologista para avaliação retiniana . Apresentava acuidade visual com correção de 20/100 no olho esquerdo e 20/20 no olho direito. A avaliação do segmento anterior era normal em ambos os olhos. No exame de fundo de olho e retinografia fluoresceínica apresentava numerosas drussas pequenas e edema macular cistóide devido a vazamentos de alguns pólipos vasculares coroidianos na arcada vascular superior e ainda fluido sub-retiniano e alteração cística no OCT . O olho direito apresentava angiografia fluoresceínica da retina e OCT normais.A paciente recusou-se a se submeter a vídeoangiografia com indocianina verde. A paciente foi tratada com injeção intravítrea de Ranibizumab como monoterapia, sendo uma injeção a cada quatro semanas, três injeções em três meses. RESULTADOS: A paciente apresentou resolução da alteração cística e do fluido sub-retiniano, ambos presentes no OCT prévio ao tratamento no olho esquerdo. A acuidade visual melhorou para 20/25 após 6 meses de tratamento. A paciente permanence com acuidade visual estável de 20/25 após 18 meses de acompanhamento. CONCLUSÃO: Reportamos um caso de paciente com edema macular cistóide originada da vasculopatia coroidiana polipoidal que respondeu ao tratamento com Ranibizumab intravítrea, como monoterapia com desaparecimento do fluido sub-retiniano e da alteração cística no OCT tendo cessado o vazamento dos pólipos que eram a causa do edema macular cistóde.

Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis.

The purpose of the study was to report a case of choroidal neovascularization (CNV) secondary to ocular toxoplasmosis in an 18-year-old female patient. She was treated with a single intravitreal injection of ranibizumab. The CNV resolved as confirmed by fluorescein angiography and optical coherence tomography (OCT). The visual acuity improved to 20/30, which was maintained till the last follow-up visit at two years, without requisition of a repeat injection.

Combination treatment of low fluence photodynamic therapy and intravitreal ranibizumab for choroidal neovascular membrane secondary to angioid streaks in Paget's disease – 12 month results.

Angioid streaks also called Knapp striae are small breaks in the Bruch's membrane and have been reported with a host of systemic diseases. Rupture of streaks or development of secondary choroidal neovascular membrane (CNVM) carries a dismal visual prognosis. We report the successful treatment of CNVM secondary to Paget's disease using low fluence photodynamic therapy (PDT) and intravitreal ranibizumab.